BioStock published an article on 9 March 2022 about Aptahem, which can be read in full below. Aptahem has communicated several positive news lately. Recently, the company received patent protection in Japan for patent family 2 regarding the drug...
Read MoreAptahem announces today that the production of Good Manufacturing Practice (GMP) manufacturing of the drug candidate Apta-1 successfully has been prepared by the collaboration partner LGC Biotechnologies in the USA, according to timeplan. The GMP manufactured Apta-1 will be...
Read MoreAptahem can today announce that in addition to previously reported positive preliminary data, the Toronto team has, from further studies, found essential positive effects in a Corona virus challenge induced Acute Lung Injury model with Apta-1 treatment. Studies show...
Read MoreAptahem AB (publ) announces today that the company has received patent protection in Japan for patent family 2 from the Japanese Patent Office (JPO). With JPO’s approval of patent application 2020-519806, the protection of the company’s drug candidate Apta-1...
Read MoreBioStock published an article on 4 February 2022 about Aptahem, which can be read in full below. Aptahem has recently recruited to fill three key positions ahead of the phase I studies planned with sepsis candidate Apta-1. Karin Aschan...
Read MoreAptahem (publ) announces today that Thomas Rupp has been appointed CMC Director in the company. Thomas has worked with Aptahem for several year in the role as aptamer expert, but he will now also take on the role as...
Read MoreAptahem (publ) announces today that Maria Ekblad has been appointed new Chief Operating Officer (COO) in the company as of 14 January 2022. Maria has long and solid experience from the pharmaceutical industry where she has held senior management...
Read MoreAptahem (publ) announces today that the company has signed an agreement to initiate activities (Start Up Agreement, SUA) with the clinical contract research organization (CRO) The Centre for Human Drug Research (CHDR) in the Netherlands to prepare the upcoming...
Read MoreAptahem AB (publ) announces today that in all countries in Europe where the company has applied for patent protection now have validated and approved the patent family 2. The patent has been published with patent number 3691655. With these...
Read MoreBioStock published an article on 2 December 2021 about Aptahem, which can be read in full below. Aptahem’s collaboration with Örebro University recently led to a research breakthrough regarding a newfound pharmacological mechanism behind Aptahem’s sepsis treatment Apta-1. BioStock...
Read More